NeuroDiscovery closes IPO
Friday, 12 August, 2005
Perth-based neurology-focused biotech company NeuroDiscovery (ASX:NDL) has closed its $1.5 million IPO and completed its acquisition of UK-based NeuroSolutions.
NeuroDiscovery offered 7.5 million shares at an issue price of AUD$0.20 each to raise the $1.5 million. NeuroSolutions - which has a mature pipeline of programs for the treatment of pain - is expected to commence Phase I and II clinical trials in the next 18 months.
NeuroDiscovery expects to list on the ASX on Monday 15 August.
Bird flu found in Victorian egg farm, returned traveller
Two separate instances of avian influenza (bird flu) were reported in Victoria yesterday —...
Cell-mapping project to uncover genetic fingerprints of disease
The $27m project will see researchers map 50 million human cells from 10,000 people to identify...
People with autism appear predisposed to PTSD
While recent studies in humans have highlighted the co-occurrence of ASD and PTSD, the link...
